ImmunoGen, Inc. Announces FDA Acceptance of IND for Company’s Novel EGFR-Targeting ADC, IMGN289


•     antibody-drug conjugate (ADC) on track to begin human clinical testing for treatment of EGFR-positive tumors in 4Q2013.
•    IMGN289 is a potential new treatment for lung, head and neck, and other EGFR-positive solid tumors, including ones not effectively treated with EGFR-directed therapies today.
•    Impressive IMGN289 efficacy in multiple EGFR-positive cancer models presented at 2013 American Association for Cancer Research (AACR).
WALTHAM, Mass.–(BUSINESS WIRE)– , (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its Targeted Antibody Payload (TAP) ADC technology, today announced that the Company’s IMGN289 Investigational New Drug (IND) application has been accepted by the US FDA and is now active. This enables ImmunoGen to advance IMGN289 into human clinical testing, expected to start in 4Q2013. This is the third IND for a novel, wholly owned anticancer compound to be submitted by ImmunoGen and accepted by the FDA in the past two years.
“We believe IMGN289 has the potential to be an important new therapy for many cancers, including squamous cell lung cancers and head and neck cancers, which have highly limited treatment options today,” commented Dr. Charles Morris, EVP and Chief Development Officer. “Based on its profile, we expect IMGN289 to be more active than existing EGFR-directed therapies against tumors with high EGFR expression and also to be effective for some tumor types where existing therapies have not demonstrated meaningful efficacy.”
About IMGN289
IMGN289, an ADC, is a potential new treatment for lung, head and neck, and other EGFR-positive solid tumors. It is designed to bind to and kill cancer cells that highly express EGFR.
IMGN289 contains an EGFR-targeting antibody developed by ImmunoGen that, in preclinical testing, demonstrated marked anticancer activity against EGFR-positive tumors responsive to EGFR inhibitors…Read more

Pharmalive – The Pulse of the Pharmaceutical Industry

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS